Anti-HIV therapy with AZT prodrugs: AZT phosphonate derivatives, current state and prospects

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 6, 2010, Pages 701-714

  Khandazhinskaya, Anastasiya ^a   Matyugina, Elena ^a   Shirokova, Elena ^a  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

Author keywords

Anti HIV; AZT; Phosphazide; Phosphonates; Prodrugs

Indexed keywords

ACICLOVIR; DIDANOSINE; FOSCARNET; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NIKAVIR; PHOSPHAZIDE; PRODRUG; RITONAVIR PLUS SAQUINAVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VALACICLOVIR; VALCYCLOVIR; ZIDOVUDINE; ZIDOVUDINE 5' AMINOCARBONYLPHOSPHONIC ACID; ZIDOVUDINE 5' ETHOXYCARBONYLPHOSPHONIC ACID; ZIDOVUDINE 5' PHOSPHATE; ZIDOVUDINE DERIVATIVE; ZIDOVUDINE HYDROGENPHOSPHONIC ACID; ZIDOVUDINE PHOSPHONIC ACID DERIVATIVE; ZIDOVUDINE PHOSPHORAMIDATE; PHOSPHONIC ACID DERIVATIVE;

ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; CENTRAL NERVOUS SYSTEM DEPRESSION; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; DNA DAMAGE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPEPSIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; LD 50; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOTOR DYSFUNCTION; NONHUMAN; REVIEW; SLOW DRUG RELEASE; STRUCTURE ACTIVITY RELATION; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; ANIMAL; HIV INFECTIONS; TOXICITY;

HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALS; HIV INFECTIONS; HUMANS; ORGANOPHOSPHONATES; PRODRUGS; ZIDOVUDINE;

EID: 77952518302     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425251003713501     Document Type: Review

References (78)

1. De Clercq E. New development in anti-HIV chemotherapy. Biochim Biophys Acta 2002;1587:258-75
2. Groschel B, Cinatl JH, Cinatl J Jr. Viral and cellular factors for resistance against antiretroviral agents. Intervirology 1997;40:400-7
3. Antonelli G, Turriziani O, Verri A, et al. Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of thymidine kinase. AIDS Res Hum Retrovir 1996;12:223-8
4. Chariot P, Drogou I, De Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steanosis, myopathy, lactic acidosis, and mitochondial DNA depletion. J Hepatol 1999;30:156-60
5. Gelmon K, Montaner JSG, Fanning M, et al. Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS 1989;3(9):555-61
6. Pan-Zhou X-R, Cui L, Zhou X-J, et al. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob Agents Chemother 2000;44:496-503
7. Chiao SK, Romero DL, Johnson DE. Current HIV therapeutics: mechanistic and chemical determinants of toxicity. Curr Opin Drug Discov Devel 2009;12(1):53-60
8. Kellam P, Boucher CA, Larder BA. Fifth mutations in HIV reverse transcriptase contributes to the development of high level resistance to zidovudine. Proc Natl Acad Sci USA 1992;89:1934-8
9. Ren J, Esnouf RM, Hopkins AL, et al. 3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. Proc Natl Acad Sci USA 1998;95:9518-23
10. Stańczak A, Ferra A. Prodrugs and soft drugs. Pharmacol Rep 2006;58(5):599-613
11. Beaumont K, Webster R, Gardner I, Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 2003;4(6):461-85
12. Calogeropoulou T, Detsi A, Lekkas E, Koufaki M. Strategies in the design of prodrugs of anti-HIV agents. Curr Top Med Chem 2003;3(13):1467-95
13. Tarusova NB, Khorlin AA, Kraevskii AA, et al. Inhibition of reproduction of HIV in cell culture by 5'-phosphonates of 3'-azido-2', 3'-dideoxynucleosides. Mol Biol 1989;23(6):1716-24
14. Tarussova NB, Krayevsky AA, Korneyeva MN, Georgii A. New phosphonate derivatives of nucleoside analogues as anti-HIV agents. Collection Chem Commun 1990;44(2):133-6
15. Karamov EV, Lukashov VV, Tarussova NB, et al. Inhibition of human immunodeficiency virus in cell cultures with 5'-phosphites of 3'-azido-2', 3'-dideoxynucleosides. Mol Biol 1990;24(6):1695-701
16. Krayevsky AA, Tarussova NB, Zhu Q-Y, et al. 5'-Hydrogenphosphonates and 5'-methylphosphonates of sugar modified pyrimidine nucleosides as potential anti-HIV-1 agents. Nucleos Nucleot 1992;11(2-4):177-96
17. Tarussova NB, Kukhanova MK, Kraevsky AA, et al. Inhibition of HIV production by 5'-hydrogenphosphonates of 3'-azido-2', 3'-dideoxynucleosides. Nucleos Nucleot 1991;10(1-3):351-4
18. Kukhanova MK, Kuznetsova EV, Arzumanov AA, Krayevsky AA. Phosphate-modified nucleotides: conversions in human serum. Nucleos Nucleot 1995;14(3-5):997-1000
19. Machado J, Salomon H, Oliveira M, et al. Antiviral activity and resistance profile of phosphazid - a novel prodrug of AZT. Nucleos Nucleot 1999;18(4-5):901-6
20. Khorlin AA, Tarusova NB, Dyatkina NB, et al. 5'-Phosphonates of 2', 3'-dideoxynucleosides. RF1548182; 1992, US5043437; 1991, EP0354246; 1994, Japan 0354246 B1; 1995, Korean 106957; 1996
21. Yurin O, Kravtchenko A, Serebrovskaya L, et al. The phase 1 of the clinical trial of 'Phosphazid', the new reverse transcriptase inhibitor [abstract]. 4th International Congress on drug therapy in HIV-infection; Glasgow, UK; 1998;12(4):240
22. Yurin OU, Krayevsky AA, Afonina Yu, et al. Phosphazid - a new antiretroviral drug. Epidemiol Infect Dis (Russian) 2001;1:43-5
23. Gosselin G, Perigaud C, Lefebvre I, et al. 5'-Hydrogenphosphonates of anti-HIV nucleoside analogues revisited: controversial mode of action. Antiviral Res 1993;22(2-3):143-53
24. McGuigan C, Bellevergue P, Jones BCNM, et al. Alkyl hydrogen phosphonate derivatives of the anti-HIV agent AZT may be less toxic than the parental nucleoside analogue. Antivir Chem Chemother 1994;5:271-7
25. Galegov G. Nikavir (Phosphazide), an antiretroviral agent: anti-HIV activity, toxicology, pharmacokinetics and some perspectives of clinical use. Antibiot Chemother (Russian) 2004;49(7):3-8
26. Skoblov Yu, Karpenko I, Shirokova E, et al. Intracellular metabolism and pharmacokinetics of 5'-hydrogenphosphonate of 3'-azido-2', 3'-dideoxythymidine, a prodrug of 3'-azido-2', 3'-dideoxythymidine. Antiviral Res 2004;63(2):107-13
27. Kukhanova MK, Shirokova EA. 5'-O-modified nucleoside analogues as prodrugs of anti-HIV agents. Front Nucleic Acids 2005;339-41
28. Yurin O, Kravtchenko A, Afonina L, et al. Treatment of the patients with intolerance to AZT by phosphazid [abstract]. 5 International Congress on drug therapy in HIV-infection; Glasgow, UK; 2001;14(Suppl 4). p. 13
29. Kravtchenko AV. Application of Nikavir in HEART. Med Tribune 2004;2:90-2, 166-72 (Rus)
30. Yurin O, Kravtchenko A, Kanestri V, et al. First experience of the application of (phosphazide) the new nucleotide analogue in HAART [abstract]. 13th International AIDS Conference; Durban, South Africa; 2000; Abstract book V.1:TuPeB3205
31. Kravtchenko AV, Salamov GG, Bogoslovskaya EV, et al. Three-component combined antiretroviral therapy using HIV reverse transcriptase inhibitors. Epidemiol Infect Dis 2001;4:32-5 (Rus)
32. Kravtchenko AV, Sitdykova YuP, Serebrovskaya LV, et al. Combined antiretroviral therapy of HIV infected patients using 'reinforced' HIV protease inhibitors. Infect Dis 2003;1(1):14-19 (Rus)
33. Pokrovskii VV, Yurin OG, Belyaeva VV, et al. Clinical diagnostics and treatment of HIV infection (Recommendations for students, interns, residents and doctors of other specialities). Moscow: GOU VUNMTs, Ministry of Health of Russian Federation; 2001, (Rus)
34. Detkova NV. Chemoprophylaxis of HIV transmission from mother to the child. Thesis of Doctor of medical sciences, Moscow; 2003, (Rus)
35. Detkova NV, Sokolova EV, Bobkova MR, et al. Nevirapin (Viramune), a drug for prevention of HIV transmission from mother to child. Epidemiol Infect Dis (Russian) 2003;6:55-7
36. Ivanova EI, Vorobyeva NN. Nicavir in perinatal chemoprophylaxis. Oncology-XXI century. IV (XIII) International conference, Vietnam; 2009. p. 88-91
37. Mirzoev T. Chemoprophylaxis of vertical HIV transmission from mother to child. Doctor In Charge 2005;10:20-6 (Rus)
38. Yurin O, Kravtchenko A, Afonina L, et al. Treatment of the patients with intolerance to AZT by phosphazid [abstract]. 8th International Congress on drug therapy in HIV-infection, Glasgow, UK; 2006. p. 395
39. Ivanova ES, Vorobyova NN, Krasnoperova NN, et al. Prevention of HIV infecting of medical personnel. Materials of scientific session of Vagner State Medical Academy. Perm' 2007EA: 110-12
40. Orders of Ministry of Health of Russian Federation No 606 of 19.12.03 and No 375 of 30.05.05. Approval of Instruction on prophylaxis of transmission of HIV infection from mother to child and an application form of informed consent on HIV chemoprophylaxis (Rus)
41. Kravtchenko AV, Salamov GG, Serebrovskaya LV, et al. The first experience of HAART with phosphazide + didanosine + nevirapine in HIV-infected patients in Russia [abstract 3]. 5th International Conference on Drug Therapy, Glasgow, Scotland; 2000
42. Sitdykova YR, Serebrovskaya LV, Kravchenko AV. Immune reconstitution on treatment of HIV-infected patients with phosphazide, didanosine and saquinavir/ritonavir once daily in Russia [abstract 2.7/1]. 9th EACS Warsaw, Poland; 2003
43. Pokrovsky AG, Pronayeva TR, Fedyuk NV, et al. Anti-HIV activity of novel phosphonate derivatives of Azt, d4T, and ddA. Nucleosides Nucleotides Nucleic Acids 2001;20(4-7):767-9
44. Khandazhinskaya AL, Shirokova EA, Karpenko IL, et al. P- (alkyl) -nucleoside 5'-hydrogenphosphonates as depot forms of antiviral nucleotide analogues. Nucleosides Nucleotides Nucleic Acids 2000;19:1795-804
45. Jin Y, Xing L, Tian Y, et al. Self-assembled drug delivery systems. Part 4. In vitro/in vivo studies of the self-assemblies of cholesteryl-phosphonyl zidovudine. Int J Pharm 2009;381(1):40-8
46. Shirokova EA, Jasko MV, Khandazhinskaya AL, et al. Uncharged AZT and D4T derivatives of phosphonoformic and phosphonoacetic acids as anti-HIV pronucleosides. J Med Chem 2004;47(14):3606-14
47. Shirokova EA, Jasko MV, Khandazhinskaya AL, et al. New Lipophilic Derivatives of AZT and D4T 5'-Phosphonates. Nucleosides Nucleotides Nucleic Acids 2003;22:981-5
48. Shirokova EA, Ias'ko MV, Khandazhinskaia AL, et al. New phosphonoformic acid derivatives of 3'-azido-3'-deoxythymidine. Bioorg Khim 2004;30(3):273-80 (Rus)
49. Szymanska A, Szymczak M, Boryski J, et al. Aryl nucleoside H-phosphonates. Part 15: synthesis, properties and, anti-HIV activity of aryl nucleoside 5'-alpha-hydroxyphosphonates. Bioorg Med Chem 2005;14(6):1924-34
50. Puech F, Gosselin G, Balzarini J, et al. Synthesis and biological evaluation of dinucleoside methylphosphonates of 3'-azido-3'-deoxythymidine and 2', 3'-dideoxycytidine. Antiviral Res 1990;14(1):11-23
51. Meier C, Aubertin A-M, De Monte M, et al. Synthesis and antiviral evaluation of sate-foscarnet prodrugs and new foscarnet-AZT conjugates. Antivir Chem Chemother, 1998;9(1):41-52
52. Meier C, Habel L, Laux W, et al. Homo dinucleoside-alpha- hydroxyphosphonate diesters as prodrugs of the antiviral nucleoside analogues 2', 3'-dideoxythymidine and 3'-azido-2', 3'-dideoxythymidine. Nucleosides Nucleotides 1995;14(3-5):759-62
53. Balzarini J, Herdewijn P, Pauwels R, et al. Alpha, beta and beta, gamma-methylene 5'-phosphonate derivatives of 3'-azido-2', 3'-dideoxythymidine- 5'-triphosphate. Biochem Pharmacol 1988;37(12):2395-403
54. Jie L, Van Aerschot A, Balzarini J, et al. Synthesis and anti-hiv evaluation of some 5'-o-phosphonomethyl-2', 3'-dideoxynucleosides [abstract 22]. Antiviral Res 1990;0(Suppl 1):51
55. Jie L, Van Aerschot A, Balzarini J, et al. 5'-O-Phosphonomethyl-2', 3'-dideoxynucleosides: synthesis and anti-HIV activity. J Med Chem 1990;33(9):2481-7
56. Freeman GA, Rideout JL, Miller WH, Reardon JE. 3'-Azido-3', 5'-dideoxythymidine-5'-methylphosphonic acid diphosphates synthesis and HIV-1 reverse transcriptase inhibition. J Med Chem 1992;35(17):3192-6
57. Mackman RL, Zhang L, Prasad V, et al. Synthesis and anti-HIV activity of cyclic pyrimidine phosphonomethoxy nucleosides and their prodrugs: a comparison of phosphonates and corresponding nucleosides. Nucleosides Nucleotides Nucleic Acids 2007;26(6-7):573-7
58. Mackman RL, Zhang L, Prasad V, et al. Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs. Bioorg Med Chem 2007;15(16):5519-28
59. Krayevsky A, Tarussova N, Zhu Q, et al. New 5'-phosphonates of sugar-modified nucleosides as inhibitors of HIV production (translation). Molekulyarnaya Biologiya 1992;26(3):624-34
60. Mamaeva OA, Plyasunova OA, Pokrovskii AG, et al. Anti-HIV activity of azidothymidine and fluorothymidine 5'-phosphonates. Molekulyarnaya Biologiya 1994;28(1):90-3
61. Dyatkina N, Arzumanov A, Krayevsky A, et al. Synthesis and antiviral activity of some fluorinated nucleotide derivatives. Nucleosides Nucleotides 1994;13(1-3):325-37
62. Egron D, Arzumanov AA, Dyatkina NB, et al. Synthesis, anti-HIV activity, and stability studies of 5[prime prime or minute]-phosphorofluoridate derivatives of AZT. Bioorg Chem 2001;29(6):333-44
63. Egron D, Arzumanov AA, Dyatkina NB, et al. Synthesis, anti-HIV activity and stability studies of 3'-azido-2', 3'-dideoxythymidine 5'-fluorophosphate. Nucleosides Nucleotides 1999;18(4-5):983-4
64. Jasko M, Shipitsyn A, Khandazhinskaya A, et al. New derivatives of alkyl- and aminocarbonylphosphonic acids containing 3'-azido-3'-deoxythymidine. Russ J Bioorgan Chem 2006;32(6):542-6
65. Rosowsky A, Fu HN, Pai N, et al. Synthesis and in vitro activity of long-chain 5'-o-[(alkoxycarbonyl) phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and azt- and foscarnet-resistant strains of HIV-1. J Med Chem 1997;40(16):2482-90
66. Kong XB, Zhu QY, Ruprecht RM, et al. Synergistic inhibition of Human Immunodeficiency Virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2', 3'-dideoxythymidine. Antimicrob Agents Chemother 1991;35(10):2003-11
67. Hammond JL, Koontz DL, Bazmi HZ, et al. Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant Human Immunodeficiency Virus type 1 and select for resistance mutations that suppress zidovudine resistance. Antimicrob Agents Chemother 2001;45(6):1621-8
68. Kukhanova MK, Khandazhinskaya AL, Yasko MV, et al. Modified azidothymidine 5'-phosphonate for potential antiviral preparations. EP1829885A1, WO2006/062434; 2006
69. Khandazhinskaya AL, Yanvarev DV, Jasko MV, et al. 5'-Aminocarbonyl phosphonates as new zidovudine depot forms: antiviral properties, intracellular transformations, and pharmacokinetic parameters. Drug Metab Dispos 2009;37(3):494-501
70. Kukhanova MK, Jasco MV, Shipitzyn AV, et al. New depot forms of AZT and 3TC based on their phosphonate derivatives: anti-HIV activity and pharmacokinetic parameters. Nucleic Acids Symp Ser (Oxf) 2008; (52) :597-8
71. Drontle DP, Wagner CR. Designing a pronucleotide stratagem: lessons from amino acid phosphoramidates of anticancer and antiviral pyrimidines. Mini Rev Med Chem 2004;4(4):409-19
72. Chang SL, Griesgraber W, Southern PJ, Wagner CR. Amino acid phosphoramidate monoesters of 3'-azido-3'-deoxythymidine: relationship between antiviral potency and intracellular metabolism. J Med Chem 2001;44(2):223-1
73. Aquaro S, Wedgwood O, Yarnold C, et al. Activities of masked 2', 3'-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophages. Antimicrob Agents Chemother 2000;44(1):173-7
74. Venkatachalam T, Samuel P, Qazi S, Uckun F. Effect of change in nucleoside structure on the activation and antiviral activity of phosphoramidate derivatives. Bioorg Med Chem 2005;13(18):5408-23
75. Kinchington D, Harvey JJ, O'Connor TJ, et al. Comparison of antiviral effects of zidovudine phosphoramidate and phosphorodiamidate derivatives against HIV and ULV in vitro. Antivir Chem Chemother 1992;3(2):107-12
76. De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006;147:1-11
77. Rosowsky A, Saha J, Fazely F, et al. Inhibition of HIV-1 replication by phosphonoformate esters of 3'-azido-3'-deoxythymidine. Biochem Biophys Res Commun, 1990;172(1):288-94
78. Piantadosi C, Marasco JR CJ, Morris-Natschke SL, et al. Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity. J Med Chem 1991;34(4):1408-14